Diagnosis & Differentiation
Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma
Lung Cancer 2026 September [Link] Roberta Noberini, Ioanna Bischinioti, Simone Zanetti, Alessandro Vai, Giulia Sedda, Eltjona Mane, Claudia Bardoni, Giulia Robusti, Marianna D’Ercole, Rosanna Mancari, Ugo Cavallaro, Nicoletta Colombo, Luca Bertolaccini, Mariano Lombardi, Nicola Fusco, Lorenzo Spaggiari, Domenico Galetta, Tiziana Bonaldi Abstract Pleural mesothelioma (PM) is an aggressive tumor that arises from mesothelial cells as…
Read MorePrognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
NPJ Precision Oncology 2026 July 9 [Link] Justin M Bader, Ankit Dhiman, Nicole Aguirre, Kwasi Ansere Ofori, Princy Gupta, Hannah Qin, Anup Sharma, Owen Mitchell, Melissa Y Tjota, Aliya N Husain, Michael Drazer, Jane Churpek, Hedy Kindler, Kiran Turaga Abstract Mesothelioma is a rare cancer with poor prognosis. Somatic mutations show prognostic value in smaller…
Read MoreBAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma
Thoracic Cancer 2026 July [Link] Reina Imase, Rie Sakakibara, Susumu Kirimura, Hironori Ishibashi, Kenichi Okubo, Yasunari Miyazaki Abstract Introduction: Reliable predictive biomarkers for immune checkpoint inhibitors (ICIs) in pleural mesothelioma (PM) are lacking. Loss of BRCA1-associated protein 1 (BAP1) is a frequent molecular alteration in PM and may influence the tumor immune microenvironment. We evaluated…
Read MoreProtocol for Mesothelioma Observational study of Risk prediction and Generation of paired benign-meso tissue samples, Including a Nested MRI Substudy (Meso-ORIGINS)
BMJ Open Respiratory Research 2026 July 1 [Link] Mark D J Neilly, Alexandrea MacPherson, Laura Alexander, Nicola Walker, Caroline Kelly, Joshua Roche, Emad Abugassa, Liam Allan, Adeel Ashraf, Avinash Aujayeb, Anna Bibby, Rocco Bilancia, John Corcoran, Mahendran Chetty, Kevin Conroy, Christopher Craig, Rebecca Crook, Alveena D’Souza, Cyrus Daneshvar, Duneesha DeFoneska, Poppy Denniston, Janet Fallon, Katie…
Read MoreFrom Ascites to Malignant Peritoneal Mesothelioma: The Diagnostic Workup of a Rare Tumor
Cancer Diagnosis & Prognosis 2026 July 1 [Link] Mirko Nastasi, Chiara Ferrante, Giuliana Michelis, Enrica Branca, Manuel Ventura, Silvia Novello, Emanuela Laurita Abstract Background/aim: Ascites is a common clinical manifestation of a wide spectrum of heterogeneous underlying conditions. All possible causes of ascites should be considered in the differential diagnosis to ensure an appropriate diagnostic…
Read MoreImpact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study
In Vivo 2026 July-August [Link] Yusuke Nabe, Yasuhiro Fujita, Teppei Hashimoto, Kanji Tanaka, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Yohei Honda, Masataka Mori, Hiroki Matsumiya, Masatoshi Kanayama, Akihiro Taira, Masaru Takenaka, Koji Kuroda, Shohei Shimajiri, Fumihiro Tanaka Abstract Background/aim: While CD73 and CD155 are implicated in immune evasion and tumor progression,…
Read MoreDual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy
EJNMMI Research 2026 June 20 [Link] Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo, Jens Benn Sørensen, Carin Meltzer, Åslaug Helland, Eirik Malinen, Vilde Drageset Haakensen Abstract Background: [18F]FDG PET/CT provides a non-invasive…
Read MoreAmivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement
Journal of Thoracic Oncology 2026 June 20 [Link] Shinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, Kuan-Li Wu, Rohini Mopuri, Jennifer Ayers-Ringler, Lin Yang, Kim P Lauer, Katherine E R Smith, Yan W Asmann, Anja Roden, Farhad Kosari, Aaron S Mansfield Abstract Introduction: Diffuse pleural mesothelioma (DPM) is a lethal malignancy with no approved therapies directly targeting…
Read MoreCHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma
Clinical Lung Cancer 2026 July [Link] Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana Calabrò, Francesco Callegarin, Paola Del Bianco, Gian Luca De Salvo, Federica Pezzuto, Fiorella Calabrese, Valentina Guarneri, Andrea Dell’Amore, Federico Rea Abstract Pleural mesothelioma (PM) is…
Read MoreDevelopment and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study
The Lancet, Oncology 2026 July [Link] Kevin B W Groot Lipman, Rianne Wittenberg, Mateus de Oliveira Taveira, Illaa Smesseim, Alexander M Th Schmitz , Thierry N Boellaard 2, Kalina Chupetlovska, Mohamed A Abdelatty, Liliana Petrychenko, Neeraj Jain, Francesco M Arico, Valerio Pugliese, Robin Cornelissen, Ties A Mulders, Fenneke Zwierenga, Birgitta I Hiddinga, Mena Shenouda, Samuel…
Read More
Skip to content